Skip to main content
Local News

Promising Data from Large Alzheimer’s Study Bodes Well for This Seattle Startup

By October 5, 2022No Comments

Alzheimer’s disease researchers were buoyed by positive data released Tuesday from a large clinical trial of an experimental therapy being developed by Biogen and Eisai.

The early data suggest that the treatment, called lecanemab, eases cognitive decline. The findings also rejuvenated hope in a therapeutic approach targeting peptides that form nasty clumps in the brain of people with Alzheimer’s.

The news bodes well for companies like Seattle’s AltPep that are taking a similar path toward detecting and treating the disease.

“We see the positive results reported for lecanemab as supportive of our approach,” said AltPep founder and CEO Valerie Daggett.